These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 3713925)

  • 41. [Clinical significance of sideremia].
    TODOROVIC D; DRASTIL V
    Srp Arh Celok Lek; 1959 Sep; 87():774-81. PubMed ID: 13838630
    [No Abstract]   [Full Text] [Related]  

  • 42. [Semiological value of sideremia].
    SILVESTRI G
    Riforma Med; 1959 Nov; 73():1309-15. PubMed ID: 14446789
    [No Abstract]   [Full Text] [Related]  

  • 43. Serum enzyme changes during treatment of cancer.
    KABAKOW B; ANTOPOL W; ALBAUM HG; BLINICK G; GINZBURG L; YOUNG R
    Arch Intern Med; 1962 Sep; 110():331-8. PubMed ID: 14452939
    [No Abstract]   [Full Text] [Related]  

  • 44. [Study of the behavior of peripheral arteriovenous sideremia. II. Research on normal women in the postmenstrual and intermenstrual periods].
    TANGANELLI G; VANNUCCHI V
    Riv Crit Clin Med; 1950 Dec; 50(5-6):467-72. PubMed ID: 14845544
    [No Abstract]   [Full Text] [Related]  

  • 45. [Study of the behavior of peripheral arteriovenous sideremia. I. Research on normal subjects].
    VANNUCCHI V; TANGANELLI G
    Riv Crit Clin Med; 1950 Dec; 50(5-6):460-6. PubMed ID: 14845543
    [No Abstract]   [Full Text] [Related]  

  • 46. Impact of low serum iron on treatment outcome of PD-1 inhibitors in advanced gastric cancer.
    Yang Y; Li Y; Chen Z
    BMC Cancer; 2023 Nov; 23(1):1095. PubMed ID: 37950201
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Serum iron levels as a new biomarker in chemotherapy with leucovorin and fluorouracil plus oxaliplatin or leucovorin and fluorouracil plus irinotecan, with or without molecularly-targeted drugs.
    Ochiai T; Nishimura K; Watanabe T; Kitajima M; Nakatani A; Inou T; Shibata H; Sato T; Kishine K; Seo S; Okubo S; Futagawa S; Mashiko S; Nagaoka I
    Mol Clin Oncol; 2013 Sep; 1(5):805-810. PubMed ID: 24649250
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of serum iron levels during FOLFOX4 and FOLFIRI therapies.
    Mashiko S; Nagaoka I; Kitajima M; Watanabe T; Nishimura K; Futagawa S; Ochiai T
    Exp Ther Med; 2010 May; 1(3):507-511. PubMed ID: 22993568
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Two cases of colorectal cancer presenting with periodic, transient elevation of serum iron due to hemolysis after chemotherapy including 5-FU].
    Hosokawa Y; Motoori S; Miyazawa T; Iwamoto N; Kase Y; Kitagawa N; Saisho H; Furuse J; Itabashi M
    Gan To Kagaku Ryoho; 2010 Sep; 37(9):1805-8. PubMed ID: 20841952
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
    Voravud N; Sriuranpong V
    J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A phase I study of swainsonine in patients with advanced malignancies.
    Goss PE; Baptiste J; Fernandes B; Baker M; Dennis JW
    Cancer Res; 1994 Mar; 54(6):1450-7. PubMed ID: 8137247
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cytokine regulation of iron metabolism: effect of low-dose interleukin-2 subcutaneous therapy on ferritin, transferrin and iron blood concentrations in cancer patients.
    Lissoni P; Cazzaniga M; Ardizzoia A; Rossini F; Fiorelli G; Tancini G; Pittalis S; Barni S
    J Biol Regul Homeost Agents; 1993; 7(1):31-3. PubMed ID: 8346713
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cancer chemotherapy induces a transient increase of serum-iron level.
    Follézou JY; Bizon M
    Neoplasma; 1986; 33(2):225-31. PubMed ID: 3713925
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prediction of response to optimize outcome of treatment with erythropoietin.
    Beguin Y
    Semin Oncol; 1998 Jun; 25(3 Suppl 7):27-34. PubMed ID: 9671327
    [TBL] [Abstract][Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 3.